buspar and tingling


A new study (the ATOMIC2 trial), presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) and published simultaneously in The Lancet Respiratory Medicine, shows the antimicrobial drug azithromycin—already approved for use in multiple infections—does not prevent mild COVID-19 cases progressing to hospitalisation or death.

The study, by Dr. Timothy Hinks, John Radcliffe Hospital and University of Oxford, UK, detrol grapefruit and colleagues, shows that azithromycin should not be used as a treatment for COVID-19 and all countries must stop using it for this purpose, to prevent resistance developing to azithromycin in other infections.

The SARS-CoV-2 pandemic has not only started a rush to develop new treatments, but also investigations of already approved drugs to determine if they too can be used to treat COVID-19. Azithromycin is an antibiotic used to treat serious chest infections including pneumonias and drug-resistant tuberculosis, trachoma—a common preventable cause of blindness—sinus infections, Lyme disease, skin infections and some sexually transmitted infections such as chlamydia.

The antibacterial, anti-inflammatory and antiviral properties of azithromycin suggested it could have therapeutic potential against COVID-19. However, there is a lack of data from randomised controlled trials of azithromycin to treat mild-to-moderate COVID-19 disease. In this study, the authors assessed whether azithromycin is effective in reducing hospitalisation in patients with mild-to-moderate COVID-19. These were people with COVID-19 symptoms sufficiently severe to prompt them to seek hospital assessment, but not severe enough, initially, to require admission for oxygen therapy.

This randomised clinical trial at 19 centres in the UK enrolled adults aged 18 years and older, presenting to hospitals with clinically-diagnosed highly-probable or confirmed COVID-19 infection, with less than 14 days of symptoms, considered suitable for initial hospital assessment then treatment and/or observation at home. Patients were randomised (1:1) to azithromycin (500 mg daily orally for 14 days) or to observation at home only. The primary outcome was the difference in proportion of participants with death or hospital admission from any cause over the following 28 days.

A total of 298 participants were enrolled from June 2020 to January 2021 and 292 were included in the final analysis. The authors found no difference between the azithromycin and control groups in the risk of COVID-19 progressing to hospitalisation or death.

They explain that, in contrast to other studies the high dose of azithromycin in this new study (500 mg daily) and long duration (14 days) was selected to ensure that the trial adequately assessed potential antiviral, antibacterial and anti-inflammatory benefits. COVID-19 is considered to have a distinct early “viraemic” phase with a high viral load and a late inflammatory phase in some individuals, and therefore assessment of antiviral activity needed to be early in the disease course prior to onset of severe disease.

At the same time, it was not known what doses might be required to produce an adequate anti-inflammatory effect and so it was necessary to give a high dose of long duration to ensure the anti-inflammatory effect was tested throughout the late stage of innate/ acute phase of inflammatory cytokine dysregulation (known as the cytokine storm, which overwhelms the immune system of affected individuals and is often fatal).

Source: Read Full Article